Emerging Platform Trials for the Treatment of Newly Diagnosed and Recurrent Glioblastoma.

Authors

Deveney Franklin, Dominique M O Higgins

Published in

Hematology/oncology clinics of North America. Oct 01, 2026. Epub Oct 01, 2026.

Abstract

Glioblastoma (GBM) remains highly morbid despite maximal safe resection, radiotherapy, and chemotherapy, prompting the expansion of clinical investigation. This review examines 4 emerging therapeutic strategies for newly diagnosed and recurrent GBM that address major biological barriers to treatment: tumor immunosuppressive microenvironment, antigen heterogeneity, and the blood-brain barrier. In a subset of patients, early clinical studies demonstrate promise; however, more evidence is necessary prior to its incorporation into the mainstay therapeutic landscape.

PMID:
42823270
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.